Rocket Pharmaceuticals Inc (RCKT)
Rocket Pharmaceuticals Inc. is a late-stage biotechnology company focused on developing, manufacturing, and commercializing genetic therapies for rare and serious diseases in the United States. Its pipeline includes in vivo adeno-associated viral (AAV) programs targeting Danon disease, PKP2-related arrhythmogenic cardiomyopathy, and BAG3 dilated cardiomyopathy, with development stages ranging from Phase 2 to preclinical. The company also advances ex vivo lentiviral programs for leukocyte adhesion deficiency-I, Fanconi anemia, and pyruvate kinase deficiency. Rocket Pharmaceuticals has entered into license agreements with several research and academic institutions, including organizations in Spain, UCL Business PLC, The Regents of the University of California, and Temple University. Founded in 1999, the company is headquartered in Cranbury, New Jersey.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RCKT
|
$4.28
|
26.4% Upside
|
Undervalued
|
$9.39
|
176.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
-1.8x
|
1.6x
|
—
|
374.5 M
|
251.6 M
|
6.2%
|
79.6%
|
-7.2
|
—
|
85.9%
|
